Multiple Myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...

GSK reported positive survival data for Blenrep combined with bortezomib and dexamethasone in multiple myeloma DREAMM-7 trial, outperforming daratumumab combination therapy. GSK plans US relaunch in ...

The ability of the bone marrow to produce healthy blood cells declines significantly with age, leading to age-related ...

This looked at patients with transplant-eligible newly diagnosed multiple myeloma ... survival [PFS], as well as overall ...

Johnson & Johnson seeks US & EU approvals for Darzalex Faspro/Darzalex as subcutaneous monotherapy for high-risk smoldering multiple myeloma: Raritan, New Jersey Monday, November ...

Multiple Myeloma is a type of blood cancer that develops in plasma ... can provide patients with extended survival and ...

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

CAR T-cell therapies for hematologic malignancies have targets that are found primarily in blood, lymph nodes, and bone ...

SEQ is the first and only assay to receive Medicare coverage for MRD assessment in MCLCoverage leverages new Medicare episode pricing ...

Overall response rate (ORR): percentage ... control and longer survival, he explained. Fung is the chair of the Department of Bone Marrow Transplant and Cellular Therapies and director of the Multiple ...

Sharda Sinha's battle with Multiple Myeloma highlights the disease's dangers. Learn about its impact and significance.- Watch ...